| Trial ID: | L7245 |
| Source ID: | NCT02882477
|
| Associated Drug: |
Deferiprone
|
| Title: |
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus|Iron Metabolism Disorders|Gastroduodenal Ulcer|Optic Atrophy|Sensorineural Hearing Loss|Platelet Dysfunction
|
| Interventions: |
DRUG: Deferiprone|DRUG: Acetylcysteine|DRUG: Sitagliptin and Metformin
|
| Outcome Measures: |
Primary: Insulin levels in blood in response to Glucose Challenge - Oral Glucose tolerance test (OGTT ) and Intra venous glucose tolerance test (IVGTT), 5 months|Platelet aggregation to Adenosine diphosphate (ADP) and Collagen - blood test for Platelet function test, 5 months|Nerve conduction velocity in VEP, 5 months|HBA1C level, 5 months|daily glucose level measurement in the blood using Glucometer two to 5 times daily, 5 months|C-Peptide levels in blood in response to Glucose Challenge - Oral Glucose tolerance test ( OGTT ) and Intra venous glucose tolerance test IVGTT, 5 months |
|
| Sponsor/Collaborators: |
Sponsor: Hadassah Medical Organization
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-12
|
| Completion Date: |
2018-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-29
|
| Locations: |
Hadassah medical center, Jerusalem, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT02882477
|
